A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Rovalpituzumab tesirine (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 31 May 2017 Planned End Date changed from 2 Mar 2020 to 15 Apr 2020.
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.
- 30 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Apr 2017.